[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645611":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":25,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Ohio State University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Glucagon-Like Peptide-1 Agonist (GLP-1)","Adults currently taking a GLP-1 receptor agonist (GLP-1RA) medication for at least 3 months at a stable dose (e.g., semaglutide, liraglutide, tirzepatide, dulaglutide, or exenatide) complete a single, anonymous, online questionnaire administered via Qualtrics on Ohio State University secure servers. The survey (\\~10 minutes) collects self-reported data on demographics, general health, current GLP-1RA medication with starting and current dose, height and weight, resistance training habits in a usual week before and since starting GLP-1RA therapy (assessed with the Muscle-Strengthening Exercise Questionnaire - Long Form; Shakespear-Druery et al., 2022), perceived muscular strength, activities of daily living, fatigue, quality of life, and barriers\u002Ffacilitators to resistance training. No in-person visits, physical measurements, biospecimen collection, or follow-up contact are performed.",[14],"GLP-1RA",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Madison L Kackley, PhD","CONTACT","614-247-9650","kackley.19@osu.edu",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":24},"Sam Soufi, BS","703-321-6784","soufi.3@osu.edu",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The Ohio State University","RECRUITING","Columbus","Ohio","43210","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-82.99879,39.96118,{"lat":38,"lon":37},[41,42,43],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},{"name":22,"role":18,"phone":23,"phoneExt":7,"email":24},{"name":17,"role":44,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100645611","determination-of-resistance-training-status-for-patients-on-glucagon-like-peptide-1-receptor-agonists-100645611",false,"NCT07702461","Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists","Inclusion Criteria:\n\n* Adult aged 18 years or older\n* Currently taking a GLP-1 receptor agonist medication\n* On the GLP-1 receptor agonist for at least 3 months\n* Using the GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and\u002For weight management (self-reported)\n* Stable GLP-1 receptor agonist dose for the past 4 to 8 weeks\n* Able to read and respond to the survey in English\n* Willing and able to provide informed consent electronically\n\nExclusion Criteria:\n\n* Currently or planning to become pregnant\n* Planned bariatric surgery within the next 3 months\n* Recent bariatric surgery (within the past 3 months) or other conditions that substantially alter resistance training capacity (e.g., advanced cancer cachexia, severe mobility-limiting conditions)\n* Unable to read or respond to the survey in English","ALL","18 Years",{"count":56,"type":57},300,"ESTIMATED","1 Day","OBSERVATIONAL","This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide \\[Ozempic, Wegovy, Rybelsus\\], liraglutide \\[Saxenda, Victoza\\], or tirzepatide \\[Mounjaro, Zepbound\\]) perform resistance (strength) training before and after starting their medication.\n\nGLP-1 medications are being prescribed more and more often to help people manage type 2 diabetes and lose weight. These medications work well, but a known side effect is that people can lose lean (muscle) tissue along with fat. Losing muscle can make it harder to move, do everyday tasks, and stay strong as we age. Resistance training, things like lifting weights, using resistance bands, or doing push-ups and squats, is the most effective way to keep and build muscle. Yet most adults in the United States do not meet the recommended amount of resistance training, and very little is known about the resistance training habits of people who take GLP-1 medications.\n\nThe purpose of this research is to systematically collect information from adults using GLP-1 medications so we can better understand: how often they do resistance training before and after starting the medication; what their sessions look like (frequency, duration, intensity, muscle groups); whether their resistance training is linked to how strong they feel and how well they can carry out daily activities; and what makes resistance training easier or harder while on a GLP-1 medication.\n\nFindings will help doctors, dietitians, exercise professionals, and researchers design better guidance and interventions to protect muscle mass, physical function, and quality of life in people using GLP-1 medications.\n\nWho can join: Adults 18 years or older who are currently taking a GLP-1 receptor agonist medication for type 2 diabetes, overweight or obesity, or weight management, and who have been on the medication for at least three months at a stable dose. Participants must be able to read and respond to the survey in English. People who are pregnant or planning bariatric surgery within the next three months are not eligible.\n\nWhat participants will do: The study is a single, anonymous, online survey. Interested individuals click the survey link, review a short consent page, and indicate their willingness to participate. Eligible participants then answer questions about their background, current health, GLP-1 medication and dose, resistance training habits before and after starting the medication, self-reported strength and function, and things that make resistance training easier or harder. There are no in-person visits, no exercise tests, and no blood draws.\n\nHow long it takes: About 10 minutes total, in one online session. There is no follow-up after the survey and no compensation is offered.\n\nData privacy: The survey is anonymous. No names, email addresses, or IP addresses are collected or linked to responses. The survey runs on Qualtrics, a secure, institution-approved platform hosted on Ohio State University servers.\n\nThe research team hopes to enroll up to 200-300 adults across the United States.",[62,63],"Obesity & Overweight","Diabetes (DM)",[65,66,14,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98],"GLP-1","GLP-1 Receptor Agonist","Semaglutide","Liraglutide","Tirzepatide","Ozempic","Wegovy","Rybelsus","Mounjaro","Zepbound","Saxenda","Victoza","Muscle-strenghtening Exercise","MSEQ","Lean body mass","Sarcopenia","Muscle Preservation","Weight Loss","Weight Management","Resistance Training","Strength Training","Weightlifting","Exercise","Physical Activity","Body weight exercise","Pilates","Holistic Exercise","Physical Function","Activities of Daily Living","Quality of Life","Health Related Quality of Life","Glucagon-Like Peptide-1","Glucagon-Like Peptide-1 Receptor Agonist","Weight Loss Medication","2026-07-23",{"date":101,"type":102},"2026-07-24","ACTUAL",{"date":104,"type":102},"2026-06-12",{"date":106,"type":57},"2027-01",{"name":5,"class":6},1]